-
GlaxoSmithKline's single-pill and dual-drug AIDS treatment drug Dovito is officially approved in China
Time of Update: 2021-07-20
The world's leading multinational healthcare company GlaxoSmithKline announced today that its innovative dual-drug therapy for AIDS treatment regimens multi Wei asked ® (generic name: lamivudine more than raltegravir tablets) has been formally approved by the State Drug China Authority approved .
-
It is rumored that Hutchison Pharmaceuticals restarts Hong Kong stock IPO and plans to raise US$500 million. These three drugs are most worthy of attention
Time of Update: 2021-07-20
In 2020, Su Weiguo, chief scientific officer of Hutchison Medicine, said in an interview with Jiemian News that he would actively consider listing plans.
He Jun, CEO of Hutchison Medicine, said in an interview with Jiemian News that the drug is expected to be approved for listing within this year .
-
Nuocheng Jianhua, Dr. Jisong Cui, was selected as one of the 15 people who influenced the innovation of China's biomedical industry
Time of Update: 2021-07-20
On March 9, 2021, DeepTech's media platform SciPhi, which focuses on the content and data of the entire chain of life science industrialization, paid close attention to the important role of women in
-
Is the scarcity of samples the logic behind Hangzhou Anxu Biotech's refusal to register?
Time of Update: 2021-07-20
Before soliciting corporate problems at some medical device conferences, many companies have mentioned that it is difficult to obtain clinical samples, but in the end, there is not much change .
-
Fortune Huaning Biopharmaceuticals and China Merchants Group's health sector strategic cooperation and C round financing signing
Time of Update: 2021-07-20
At the same time, the health sector of China Merchants Group and Fortune Huaning Bio-Pharmaceuticals will also jointly integrate resources in the promotion of new drug research and development, digital production base building, and product market expansion, and launch full-chain cooperation to help Fortune Huaning Bio-Pharmaceuticals complete several important tasks as soon as possible.
-
Bayer and Yifeng jointly unveiled the "Spring Health Carnival"
Time of Update: 2021-07-20
At this health carnival, Professor Yin Chuanmin, deputy director of the Nutrition Department of the Obstetrics and Gynecology Hospital of Fudan University, was a female health trader for most families and introduced how to ensure nutritious intake through reasonable diet and improve Immunity, defense against foreign viruses and bacteria invading, clearing senescent or damaged cells, and maintaining self-stability .
-
2020 Top 15 Medical Technology Companies
Time of Update: 2021-07-20
Ellume CEO: Sean Parsons Established time: 2010 Headquarters: Brisbane The Australian company Ellume has developed the first COVID-19 test that can be sold over the counter in the United States without a doctor's prescription .
-
Xu Xiaoyan, Senior Vice President of Hisun Pharmaceutical, resigns
Time of Update: 2021-07-20
On March 9, Hisun Pharmaceutical issued an announcement that the company’s board of directors received a written resignation report from Xu Xiaoyan, the company’s senior vice president, on March 9, 2021 .
-
Youhe Pharmaceutical announces that its CTLA-4 combined with Junshi Bio-PD-1 has achieved breakthrough results in Phase I clinical trials in Australia
Time of Update: 2021-07-20
As a biomedical company dedicated to the development of tumor and immune antibody drugs with independent intellectual property rights, Youhe Pharmaceutical announced on March 4 that its anti-CTLA-4 antibody (YH001) combined with Junshi Biologics anti-PD-1 monoclonal antibody drug Terui Pritimab injection (trade name: Tuoyi®) has shown encouraging anti-tumor activity in the dose escalation phase of the Australian Phase I clinical study .
-
Junshi Biologics PD-1/TGF-β bifunctional fusion protein drug clinical trial application was accepted by NMPA
Time of Update: 2021-07-20
(Suqiao Biological), announced that its PD-1/TGF-β bifunctional fusion protein JS201 injection (project code: JS201) went smoothly It was accepted by the National Center for Drug Evaluation of China .
-
O'Tangning further expands indications for insulin combination
Time of Update: 2021-07-20
On March 5, Boehringer Ingelheim announced that its type 2 diabetes treatment drug O'Tangning (generic name: linagliptin tablets) has been approved by the State Food and Drug Administration: combined insulin therapy (with or without Metformin), on the basis of diet and exercise to improve blood sugar control in patients with type 2 diabetes .
-
Founded 7 years without income, 9 months loss exceeded 200 million, this interventional cardiovascular device company plans to IPO in Hong Kong stocks
Time of Update: 2021-07-20
The prospectus shows that Baixin'an is one of the only three domestic companies in China that has a second-generation fully degradable stent product in clinical trials.
-
Xiangxue Life Sciences introduces 100 million yuan in Series A financing to accelerate research and development in the field of cellular immunotherapy
Time of Update: 2021-07-20
According to the agreement, Huagai Medical will increase the capital of Xiangxue Life Science by 100 million yuan, of which about 595,200 yuan is included in the registered capital, and 9,994,800 yuan is included in the capital reserve .
-
Shuwen Biology asks Xian'an to enter the expert consensus of preeclampsia
Time of Update: 2021-07-20
" Shuwen Bio is a national high-tech enterprise focusing on the development, production, sales and medical testing services of in vitro diagnostic reagents.
-
[Exclusive] Gao Tejia founder Cai Dajian was fired from his wife, and the second shareholders of the company have to "grab the class to seize power"
Time of Update: 2021-07-20
(hereinafter referred to as Gaotejia), a well-known medical investment institution, Gaotejia, and two copies of Gaotejia's internal In the "Disciplinary Decision", the above three documents show that Gao Tejia will expel Cai Dajian and his managing partner Sun Jialin, and stated that "Cai Dajian is suspected of embezzlement and embezzlement of the company's huge funds, etc.
-
Northeast Pharmaceutical hires Zheng Wei as the company's deputy general manager and Zhou Kai as the chief financial officer
Time of Update: 2021-07-20
Zheng Wei as the company's deputy general manager for the same term as the eighth session of the board of directors .
, General Manager and Secretary of the Party Committee of Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co.
-
The judges cover the two major public associations of Chinese medical and aesthetics, and the 2021 new oxygen emerald doctor list witnesses the rise of female doctors
Time of Update: 2021-07-20
Huang Jinlong, a technical expert judge on the New Oxygen Emerald Doctors list and director of plastic surgery at Jiangsu Provincial Hospital of Traditional Chinese Medicine, pointed out that the medical beauty industry has developed rapidly in recent years, and a huge domestic population will be involved in the future .
-
BeiGene's application for new indications for second- or third-line non-small cell lung cancer has been accepted
Time of Update: 2021-07-20
BeiGene announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has accepted its anti-PD1 antibody Bezean® (tislelizumab) for the treatment of disease progression after platinum-based chemotherapy Application for new indications for the second or third-line locally advanced or metastatic non-small cell lung cancer (NSCLC) patients .
-
In 2020, BY-HEALTH achieved a net profit of 1.524 billion yuan attributable to the parent, a year-on-year increase of 528.29%
Time of Update: 2021-07-20
In recent years, BY-HEALTH has continued to increase product R&D efforts, focusing on improving product technology content to expand product core competitive advantages; at the same time, it has accelerated digital construction and promoted user asset operations, achieving significant performance growth and leading market share .
-
Leadstar Bio launches clinical intelligence analysis platform to help research and development of new tumor drugs
Time of Update: 2021-07-20
(hereinafter referred to as "Leadstar Bio"), innovatively uses the panoramic data of "comprehensive genes" + "deep clinical" , A new business model that combines artificial intelligence systems and data-driven algorithms has great potential in the process of helping oncology drug innovation and development, and provides powerful data solutions for cancer translational research and oncology drug clinical development .
